Revier Therapeutics has closed a €6 ($6.9) million seed financing and the launch of its operations.  

The company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.  

The financing was led by the KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. 

Funding from the round will support development of Revier’s preclinical cardiometabolic pipeline, including its lead programme in heart failure with preserved ejection fraction (HFpEF) and its second programme in atherosclerotic cardiovascular disease (ASCVD). 

“Despite significant progress in cardiovascular medicine, millions of patients with HFpEF and ASCVD still to date face limited targeted treatment options,” said Professor Eva van Rooij, Co-Founder and Chief Executive Officer of Revier Therapeutics. “We believe the next generation of cardiometabolic medicines needs to address the underlying disease-driving biology to deliver impactful and long-term solutions for patients. Our mission is to translate the scientific potential of class IIa HDAC inhibition into a pipeline of novel therapies and rapidly advance our lead programmes toward the clinic to create long-term value for both patients and the broader healthcare ecosystem.” 

HDACs play a functional role in a variety of severe diseases. Pioneering discoveries, including foundational work at Heidelberg University led by Professor Johannes Backs, Revier’s scientific founder, defined the specific impact of class IIa HDACs on cardiometabolic diseases. 

Professor Backs added: “While first generation HDAC inhibitors broadly targeted multiple HDAC classes resulting in dose-limiting side effects, Revier’s first-in-class small molecules selectively target class IIa HDACs. These compounds specifically inhibit the disease-driving enzymatic activity while preserving the essential functions of class IIa HDACs and canonical class I HDACs. This precise mode of action is designed to be therapeutically effective while maintaining a beneficial safety profile.”